Ethics Committee, HKEC

3 Lok Man Road
Chai Wan
Hong Kong

Dr. IP Tai Pang
Senior Medical Officer

Dept. of Medicine & Rehabilitation
TWEH

29 October 2010

Ref: HKEC-2010-053

Dear Dr. IP,

The Ethics Committee (EC) of HKEC is authorized by the Cluster Chief Executive to review and monitor clinical research. It serves to ensure that research complies with the Declaration of Helsinki, ICH GCP Guidelines, local regulations and HA policy. It has the authority to approve, require modifications in (to secure approval), or disapprove research. This Committee has power to terminate/suspend a research at any time if there is evidence to indicate that the above principles and requirements have been violated.

The Committee has reviewed your protocol amendment application on 29 October 2010 by an expedited process, and reached the following decision basing on the documents submitted.

The Committee approves your application and the following documents, and requires you to adhere to the attached conditions:

Title of Study	A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus
List of investigators	1. Dr. IP Tai Pang, SMO(Med & Rehab), TWEH 2. Dr. SIU Shing Chung, Cons(Med & Rehab), TWEH 3. Dr. LEE Yee, MO(Med & Rehab), TWEH
Protocol title and version	N.A.
Consent Form versions	N.A.
Information sheet title and versions	N.A.
Certificate of indemnity/insurance	N.A.

3 Lok Man Road, Chai Wan, Hong Kong 香港柴灣樂民道三號 Tel 電話 : +852 2595 6111 Fax 傳真 : +852 2515 0794

Other Documents	1. English Hypoglycemia Study Diary (Version: CLAF237A23135-Hypoglycemia-HKENG-31Aug10) 2. Chinese Hypoglycemia Study Diary (Version: CLAF237A23135-Hypoglycemia-HKCHIN-31Aug10) 3. English Insulin Diary (Version: CLAF237A23135-Insulindiary-HKENG-27Sep10) 4. Chinese Insulin Diary (Version: CLAF237A23135-Insulindiary-HKCHIN-27Sep10)
Conditions	1. The Principal Investigator is responsible and accountable for the confidentiality of the personal data of the study subjects they hold. The Principal Investigator must also ensure that there is appropriate arrangement to protect the security of personal data when it is stored, sent or received. 2. Do not deviate from, or make changes to the study protocol without prior written EC approval, except when it is necessary to eliminate immediate hazards to research subjects or when the change involves only logistical or administrative issues. 3. Report the following to EC/IRB: (i) study protocol or consent document change (use 'HKECRE001F7')*, (ii) serious adverse event (use 'HKECRE001F8')*, (iii) study progress (use 'HKECRE001F9')* (iv) new information that may be relevant to a subject's willingness to continue participation in the study. 4. Report first study progress to EC/IRB by 1 September 2011 and thereafter at 12 monthly intervals until study closure. 5. Submit Research Final Report Form (use 'HKECRE001F9b')* to EC/IRB upon completion of study.

** Download forms from the HKEC intranet for use*

Yours Sincerely,

Dr. S K CHOW
Chairman of EC, HKEC

c.c. COS(Med & Rehab), TWEH

香港中文大學醫學院
Faculty Of Medicine
The Chinese University Of Hong Kong

醫院管理局
新界東醫院聯網
Hospital Authority
New Territories East Cluster

Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee

香港中文大學-新界東醫院聯網 臨床研究倫理 聯席委員會

Flat 3C, Block B, Staff Quarters, Prince of Wales Hospital, Shatin, HK
Tel : (852) 2632 3935 / 2144 5926 Fax : (852) 2646 6653 Website : http://www.crec.cuhk.edu.hk

To: Dr. Risa OZAKI (Principal Investigator)
Dept. of Medicine & Therapeutics
Prince of Wales Hospital

Ethics Approval of Research Protocol

CREC Ref. No.:	**CRE-2010.347-T**
Date of Approval:	**03 August 2010***
Date of #Amendment(s) Approval:	**12 October 2010**
Protocol No.:	**CLAF237A23135**
Study Title:	**A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus**
Investigator(s):	**Risa OZAKI, Juliana Chung Ngor CHAN, Wing Yee SO, Ronald Ching Wan MA, Andrea On Yan LUK, Vanessa Wan Sze NG, Wing Yan LAU, Zhao Wei TING and Kitty Kit Ting CHEUNG**
Remark(s):	**1) Insurance covers study period until the end of the clinical trial.** **2) Composition Form as required is attached.**

I write to inform you that ethics approval has been given for you to conduct the captioned study in accordance with the following document(s) submitted:

- Clinical Trial Protocol Study, dated 28 June 2010
- Investigator's Brochure, Edition 14, dated 27 May 2010
- Patient Information Sheet and Informed Consent Form, English Version (Version: IC-CLAF237A23135-HKENG-08Jul2010-PWH)
- Patient Information Sheet and Informed Consent Form, Chinese Version (Version: IC-CLAF237A23135-HKCHIN-08Jul2010-PWH)
- Emergency Telephone Contact Card, Chinese Version
- Certificate of Insurance (Policy No. 14-001179-130113/14-001179-130190) dated 08 June 2010 and insurance covers until the end of study

Amendment(s) dated 10 September 2010

- Clinical Trial Protocol CLAF237A23135, dated 08 July 2010
- Protocol Amendment Application and Supplementary Information Report Form
- Hypoglycemia Study Diary, English and Chinese Versions:
  - CLAF237A23135-Hypoglycemia-HKENG-31Aug2010
  - CLAF237A23135-Hypoglycemia-HKCHIN-31Aug2010
- Insulin Diary, English and Chinese Version:
  - CLAF237A23135-Insulindiary-HKENG-31Aug10
  - CLAF237A23135-Insulindiary-HKCHIN-31Aug10

香港中文大學醫學院
Faculty Of Medicine
The Chinese University Of Hong Kong

醫院管理局
新界東醫院聯網
Hospital Authority
New Territories East Cluster

Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee

香港中文大學-新界東醫院聯網 臨床研究倫理 聯席委員會

Flat 3C, Block B, Staff Quarters, Prince of Wales Hospital, Shatin, HK
Tel : (852) 2632 3935 / 2144 5926 Fax : (852) 2646 6653 Website : http://www.crec.cuhk.edu.hk

CREC Ref. No.:	**CRE-2010.347-T**
Date of #Amendment(s) Approval:	**12 October 2010**
Protocol No.:	**CLAF237A23135**
Study Title:	**A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus**

15 OCT '10

#Amendment(s) dated 05 October 2010

- Insulin Diary, English and Chinese Versions (track changes and clean version):
  - CLAF237A23135-Insulindiary-HKENG-27Sep10
  - CLAF237A23135-Insulindiary-HKCHIN-27Sep10

This ethics approval* will be valid for 12 months. Application for further renewal can be made by the submission of the Ethics Renewal and Research Progress Report Form to the CREC (Download the electronic form template from the http://www.crec.cuhk.edu.hk or http://ntec.home/Research%20Ethics/main.asp). You are kindly requested to report to the Committee upon completion of the project.

The Joint CUHK-NTEC Clinical Research Ethics Committee is organized and operated according to ICH-GCP and the applicable laws and regulations.

Miss Winkie Lui
CREC Officer
Joint CUHK-NTEC
Clinical Research Ethics Committee

Encl.
WL/ci

15 OCT '10

Annex

Joint CUHK-NTEC Clinical Research Ethics Committee

Composition Form (Expedited Review)

CREC Ref. No.:	**CRE-2010.347-T**
Date of Amendment(s) Approval:	**12 October 2010**

Name	Title / Occupation	Qualifications	Male / Female (M/F)	Study Reviewed by
Members : Professor Dorothy S.P.FAN	Professor, Department of Ophthalmology and Visual Sciences, CUHK	MSc, FHKAM, FCOphthHK, FRCS(Edin), FCSHK, MBChB	F	√
Professor Cheuk Chun SZETO	Professor, Department of Medicine and Therapeutics, CUHK	MBChB(CUHK), MRCP(UK), FHKCP, FHKAM, DM(CUHK), FRCP(Edin)	M	√

Miss Winkie Lui
CREC Officer
Joint CUHK-NTEC
Clinical Research Ethics Committee

Ethics Committee

Diabetes Thyroid Hormone Research Institute Pvt Ltd, Indore

Chandrakant Khushaldas
M Sc
Retd Member, Central Board of Direct Taxes
Retd Chief Commissioner of Income Tax
Chairperson

Dr S K Parwani
MS (Ophthal)
Ophthalmologist
Member Secretary

17-May-2011

To,

Dr KIRNESH PANDEY
TOTALL Diabetes Hormone Institute
A unit of Diabetes Thyroid Hormone Research Institute Pvt Ltd
BCM Health Island, PU4, Scheme 54,
Behind Prestige Management Institute,
Near Bombay Hospital, Indore – 452010 (Madhya Pradesh) INDIA

PROTOCOL CLAF237A23135 "A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to insulin with or without metformin, in patients with type-2 diabetes mellitus."

Subject: **APPROVAL OF DOCUMENTS**

Dear Dr *Kirnesh Pandey,*

The Ethics Committee, has reviewed the below mentioned documents in their meeting held on Sunday, 15-May-2011 at 10:00 Hrs and approved the above referenced research activity that will be conducted in whole or in part at TOTALL Diabetes Hormone Institute, Indore under your direction:

Documents pertaining to Study Protocol CLAF237A23135 (including version number, version date if applicable):

1. The Patient Information and Informed Consent Form Version 2 Dated 25-Jan-2011.
2. The Patient Information And Informed Consent Form Version 2 Dated 25-Jan-2011 Translated in Hindi On 1-March-2011.

The Ethics Committee has reviewed the documents and has **APPROVED IN THE PRESENTED FORM.**

You are requested to report to the Ethics Committee the following:

- Please submit the progress report of the trial on an annual basis and final report
- All deviations from, or changes of, the protocol to eliminate immediate hazards to the study subjects
- Changes that increase the risk to participating subjects and/or those that significantly affect the conduct of the study
- All serious adverse events within 7 working days of its occurrence during the conduct of the trial
- New information that may affect adversely the safety of the subjects or the conduct of the study.

I hereby confirm that this Ethics Committee is organized and operates according to ICH-GCP and the applicable laws and regulations and that at the time of the voting the required quorum was present.

The members, who attended the meeting, held on **Sunday, 15-May-2011** at **10:00 Hrs**, at BCM Health Island, PU4, Scheme 54, Behind Prestige Management Institute, Near

Members:

Prof Dr Rajendra Jain
Ph D, MBA, LL B (Hons)
Director, Prestige Institute of Management, Dewas

S C Jain
MIE (India)
Retd Suptd Engineer

S K Jain
B Com, LLB
Retd Distt & Session Judge

Dr Kamlesh Mittal
MBBS, DA (Anaesthesia)
Consultant Anaesthetist

Dr Vimal Modi
MS (Anatomy)
Asstt Professor, Deptt of Anatomy

Ms Jaishree Pingle
B Com
Journalist

P S Surana
BA, LL B
Social Worker

Dr Suraj Tripathi
MD (Pharmacology)
Associate Professor, Deptt of Pharmacology

Ethics Committee

Diabetes Thyroid Hormone Research Institute Pvt Ltd, Indore

Chandrakant Khushaldas
M Sc
Retd Member, Central Board of Direct Taxes
Retd Chief Commissioner of Income Tax
Chairperson

Dr S K Parwani
MS (Ophthal)
Ophthalmologist
Member Secretary

Members:

Prof Dr Rajendra Jain
Ph D, MBA, LL B (Hons)
Director, Prestige Institute of Management, Dewas

S C Jain
MIE (India)
Retd Suptd Engineer

S K Jain
B Com, LLB
Retd Distt & Session Judge

Dr Kamlesh Mittal
MBBS, DA (Anaesthesia)
Consultant Anaesthetist

Dr Vimal Modi
MS (Anatomy)
Asstt Professor, Deptt of Anatomy

Ms Jaishree Pingle
B Com
Journalist

P S Surana
BA, LL B
Social Worker

Dr Suraj Tripathi
MD (Pharmacology)
Associate Professor, Deptt of Pharmacology

Bombay Hospital, Indore – 452010 (Madhya Pradesh) INDIA, in which above mentioned documents were discussed are as follows:

Name	Position	Affiliation with Institution	Qualification / Profession
Mr Chandrakant Khushaldas	Chairperson	NO	M Sc/Retd Member, Central Board of Direct Taxes Retd Chief Commissioner of Income Tax
Dr S K Parwani	Member Secretary	YES	MS (Ophthal)/Ophthalmologist TOTALL Diabetes Hormone Institute, Indore (MP)
Prof Dr Rajendra Jain	Member	NO	Ph D, MBA, LL B (Hons)/Director, Prestige Institute of Management, Dewas (MP)
Mr S C Jain	Member	NO	MIE (India)/Retd Suptd Engineer
Mr S K Jain	Member	NO	B Com, LLB/ Retd Distt & Session Judge
Dr Kamlesh Mittal	Member	NO	MBBS, DA (Anaesthesia)/Consultant Anaesthetist, CHL-Apollo Hospitals, Indore (MP)
Dr Vimal Modi	Member	NO	MS (Anatomy)/Asstt Professor, Deptt of Anatomy, Index Medical College, Indore (MP)
Ms Jaishree Pingle	Member	NO	B Com/ Journalist
Mr P S Surana	Member	NO	BA, LL B/Social Worker
Dr Suraj Tripathi	Member	NO	MD (Pharmacology)/Associate Professor, Deptt of Pharmacology, Index Medical College, Indore (MP)

None of the members of study team including Principal Investigator (that is you) for above referenced study were a part of the voting procedure.

Please feel free to contact us if you have any questions or if we may be of further assistance.

Thanking you

Yours sincerely,

for Ethics Committee of Diabetes Thyroid Hormone Research Institute Pvt Ltd, Indore

FOR : ETHICS COMMITTEE OF DIABETES THYROID HORMONE RESEARCH INSTITUTE PVT. LTD. INDORE

17/5/11

Dr S K PARWANI
MEMBER SECRETARY

MEMBER SECRETARY

S.R. KALLA MEMORIAL ETHICAL COMMITTEE FOR HUMAN RESEARCH

78, Dhuleshwar Garden, Behind HSBC Bank, Sardar Patel Marg, C-Scheme, JAIPUR - 302 001
Phone: 0141-5112042, 5112043

Date .....

Date : 07 September, 2010 Ref.:94/10

Mr. B.K. Tiwari
Chairman
(B.A., DAD)

Dr. Ravi Gupta
Member Secretary
(MBBS, M.D. (Psy.))

Members:

Dr. Rakesh Yadav
MBBS, M.D. (Psy.)

Dr. J. B. Gupta
(MBBS, M.D.(Med.))

Dr. Feroz Khan
(MBBS, D.M.C.H.)

Dr. Lalit Bharadia
(MBBS, M.D. (Paediatrics), PDCC (Paediatric Gastroenterologist))

Dr. (Mrs.) Vandana Maheshwari
MBBS, M.S. (Gynae.)

Dr. (Mrs.) Madhvander Jain
MBBS, M.S. (Gynae.)

Mr. Kawal Singh
(B.Sc., LLB)

Mr. Mukesh Gupta
B.Sc., MBA (Marketing)
Director, Lions Club Jaipur Rajdhani

Mr. Ravi Kumar Sharma
(M.Com., PGDCAA)

Mr. Vishnu Kumar Paliwal
(B. Pharma)

To,

Dr. J.B. Gupta
S.R. Kalla Memorial Gastro & General Hospital,
No: 78, Dhuleshwar Garden, Behind HSBC Bank,
Sardar Patel Marg, C-Scheme,
Jaipur - 302001

Ref :- ***"A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin alone or with metformin, in patients with Type 2 diabetes mellitus".***

Study code: **Protocol CLAF237A23135**

Subject: Ethics Committee Approval for the Conduct of the Study as per Protocol **CLAF237A23135**

Dear Dr. Gupta

We have received 12 copies of following documents by your submission letter reference 1145/2010, dated 28.08.2010 for the approval:

1. The Study protocol CLAF237A23135 dated 8-July-10.
2. The Investigator Brochure Edition 14 dated 27-May-10.
3. Investigator Notification for vildagliptin/metformin: Dyspnoea (fatal) PHHY2010BR17904 dated 1-April-10
4. Investigator Notification for vildagliptin/metformin: Bronchial carcinoma (progression), blood amylase increased – PHHY2010DE05790 – dated 1 April-10
5. Investigator Notification for vildagliptin/metformin: Anal fistula – PHHY2010BR19223 dated 6-April-10.
6. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder– PHHY2010MX19011-dated 8-April-10
7. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 – dated 9-April-10

8. Investigator Notification for vildagliptin/metformin: Diabetic complication and renal disorder – PHHY2010BR19735 dated 12-April-10
9. Investigator Notification for vildagliptin/metformin: Uterine disorder– PHHY2010BE21389 – 13-April-10
10. Investigator Notification for vildagliptin/metformin: Diabetic complication (fatal), Pyelonephritis (fatal) and Anaemia (fatal) – PHHY2010MX05199 – dated 20-April-10
11. Investigator Notification for vildagliptin/metformin: Agitation – PHHY2010FR21869 dated 20-April-10
12. Investigator Notification for vildagliptin/metformin: Disorientation and Poisoning – PHHY2010AR22699 dated 20-April-10
13. Investigator Notification for vildagliptin/metformin: Nosocomial infection and Osteomyelitis dated 20-April-10
14. Investigator Notification for vildagliptin/metformin: Thyroid operation - PHHY2010BR22360 – dated 20-April-10
15. Investigator Notification for vildagliptin: Dermatitis bullous – PHHY2010FR22668 – dated 21-April-10
16. Investigator Notification for vildagliptin/metformin: Pulmonary embolism (fatal), venous insufficiency (fatal) and hypertension (fatal) – PHHY2010MX04398- dated 21-April-10
17. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823- dated 22-April-10
18. Investigator Notification for vildagliptin: Somnolence – PHHY2010ES21948 dated 22-April-10
19. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 dated 23-April-10
20. Investigator Notification for vildagliptin/metformin: Parkinsonism and Erysipelas – PHHY2010DE24400- 26-April-10
21. Investigator Notification for vildagliptin: Lymphoma (fatal) – PHHY2010AR26217 – dated 29-April-10

22. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder and nephrolithiasis – PHHY2010MX19011 dated 30-April-10
23. Investigator Notification for vildagliptin/metformin: Feeling abnormal – PHHY2010BR24339 – dated 30-April-10
24. Investigator Notification for vildagliptin/metformin: Hepatitis toxic and Barrett's oesophagus- dated 30-April-10
25. Investigator Notification for vildagliptin/metformin: Pancytopenia – PHHY2010FR26370 – dated 5- May-10
26. Investigator Notification for vildagliptin: Myeloid leukemia –PHHY2010KR26860 dated 7-May-10
27. Investigator Notification for vildagliptin/metformin:Hypertensive crisis– PHHY2010DE17676 – dated 12-May-10
28. Investigator Notification for vildagliptin/metformin: Angioplasty, Road traffic accident – PHHY2010MX28077 dated 12-May-10
29. Investigator Notification for vildagliptin/metformin: Urogenital disorder – PHFR2010GB00461 – dated 14-May-10
30. Investigator Notification for vildagliptin/metformin: Anaphylactic reaction – PHHY2010FR18881 dated 14-May-10
31. Investigator Notification for vildagliptin/metformin: Poisoning – PHHY2010MX28393 – dated 14-May-10
32. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis chronic – PHHY2010RU11562 dated 19-May-10
33. Investigator Notification for vildagliptin/metformin : Jaw operation – PHFR2010GB00532 – dated 19-May-10
34. Investigator Notification for vildagliptin: Infected skin ulcer (fatal) and osteomyelitis (fatal) – PHHY2010AR24350 dated 20-May-10
35. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis acute and Hydronephrosis – PHHY2010RU11165 dated 20-May-10.
36. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823 dated 20-May-10

37. Investigator Notification for vildagliptin/metformin: Feeling abnormal (life threatening) – PHHY2010BR31153 dated 21-May-10
38. Investigator Notification for vildagliptin/metformin: Hypertension (fatal) – PHHY2010AR31496 – dated 25-May-10
39. Investigator Notification for vildagliptin: Glaucoma – PHHY2010MX31604 – dated 25-May-10
40. Investigator Notification for vildagliptin/metformin: Hepatic failure – PHHY2010FR31991 dated 27-May-10
41. Investigator Notification for vildagliptin/metformin: Fall (fatal) – PHHY2010DE32526 - dated 28-May-10
42. Investigator Notification for vildagliptin/metformin: Neoplasm malignant (fatal) – PHHY2010MX32493 dated 28-May-10
43. Investigator Notification for vildagliptin/metformin: Diabetes insipidus (fatal), Brain oedema (fatal) and Respiratory arrest (fatal) – PHHY2010MX32892 dated 28-May-10
44. Investigator Notification for vildagliptin/metformin: Cytolytic hepatitis, Hepatotoxicity – PHHY2010FR32018 - dated 28-May-10
45. Investigator Notification for vildagliptin: Vision blurred – PHHY2010MX33002 – dated 31-May-10
46. Investigator Notification for vildagliptin/metformin: Muscle contractions involuntary and muscle rigidity – PHHY2010AR32862 dated 31-May-10
47. Investigator Notification for vildagliptin/metformin: Hepatitis toxic, Barrett's oesophagus and Haemochromatosis – PHHY2010DE25008 dated 31-May-10
48. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 31-May-10
49. Investigator Notification for vildagliptin/metformin: Cardiac valve disease – PHHY2010MX33389 dated 2-June-10
50. Investigator Notification for vildagliptin/metformin: Breast neoplasm – PHHY2009MX47365 – dated 7-June-10
51. Investigator Notification for vildagliptin/metformin: Hepatomegaly – PHHY2010FR 4686 - dated 7- June -10

52. Investigator Notification for vildagliptin: Osteoporosis – PHHY2010BR34361 –dated 7-June -10
53. Investigator Notification for vildagliptin/metformin: Knee arthroplasty PHHY2010MX34922 dated 8- June -10
54. Investigator Notification for vildagliptin: Glaucoma, Macular degeneration – PHHY2010MX31604 – dated 8- June -10
55. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic – PHHY2010MX34733 dated 8- June -10
56. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic and herpes zoster oticus – PHHY2010MX34733 - dated 9- June -10
57. Investigator Notification for vildagliptin/metformin: Hepatic failure, Pancreatic carcinoma metastatic – PHHY2010FR31991 - dated 9- June -10
58. Investigator Notification for vildagliptin: Blood pressure decreased – PHHY2010JP36133 – dated 10- June -10
59. Investigator Notification for vildagliptin/metformin: Diverticulitis– PHHY2010DE36823 dated 14- June -10
60. Investigator Notification for vildagliptin/metformin: Colitis – PHHY2010MX36727 - 15-June -10
61. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764 – dated 15- June -10
62. Investigator Notification for vildagliptin: Hypoaesthesia and large intestine perforation– PHHY2010MX36811- dated 16- June -10
63. Investigator Notification for vildagliptin/metformin: Diabetic nephropathy – PHHY2010DE23979 dated 16- June -10
64. Investigator Notification for vildagliptin/metformin: Chronic obstructive pulmonary disease – PHHY2010NO37552 dated 16- June -10
65. Investigator Notification for vildagliptin/metformin: Hepatomegaly and hepatic cirrhosis – PHHY2010FR34686 - dated 21- June -10
66. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 21- June -10

67. Investigator Notification for vildagliptin: Obesity surgery – PHHY2010BR37976 – dated 21-June -10
68. Investigator Notification for vildagliptin: Gastric ulcer perforation – PHHY2010MX38088 – dated 21- June -10
69. Investigator Notification for vildagliptin/metformin: Cardiogenic shock (fatal) and cytolytic hepatitis – PHHY2010FR38922 - dated 22- June -10
70. Investigator Notification for vildagliptin/metformin: Drug interaction – PHHY2010FR37623 - dated 24- June -10
71. Investigator Notification for vildagliptin/metformin: Irritable bowel syndrome – PHHY2010BR06953 – dated 29- June -10
72. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 30- June -10
73. Investigator Notification for vildagliptin: Delirium– PHHY2010JP40546 –dated 1-July-10
74. Investigator Notification for vildagliptin/metformin: Macular oedema – PHHY2010DE41585 – dated 1- July -10
75. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – 5-July -10
76. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 12- July -10
77. Investigator Notification for vildagliptin/metformin: Hepatitis – PHHY2010DE45018 – 16-July -10
78. Investigator Notification for vildagliptin: Hepatitis cholestatic– PHHY2010JP45330 – dated 16- July -10
79. Investigator Notification for vildagliptin: Jaundice – PHHY2010JP45195– dated 16- July -10
80. Investigator Notification for vildagliptin: Ileus – PHHY2010JP45206 – 20- July -10
81. Investigator Notification for vildagliptin/metformin: Abscess limb – PHHY2010MX44960 – 20- July -10
82. Investigator Notification for vildagliptin: Stent placement – PHHY2010AR45723-dated 22-July -10
83. Investigator Notification for vildagliptin/metformin: Traumatic lung injury – PHHY2010BR45810 – 22- July -10

84. Investigator Notification for vildagliptin/metformin: Fall (fatal), Head injury (fatal) – PHHY2010DE32526 - dated 22- July -10
85. Investigator Notification for vildagliptin/metformin: Typhoid fever– PHHY2010MX-6657 - 26- July -10
86. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764- 30- July -10
87. Investigator Notification for vildagliptin: Hepatic cirrhosis (fatal) – PHHY2010EC47345 – dated 29- July -10
88. Investigator Notification for vildagliptin/metformin: Mouth ulceration – PHHY2010GR47082 – dated 29- July -10
89. Investigator Notification for vildagliptin/metformin: Cholestasis – PHHY2010FR48667 – 3- August-10
90. The Electronic Case Report Form (eCRF) Layout dated 14-July-10.
91. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol in English.
92. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol translated in Hindi Language on 28-July-10.
93. The Glycemia Study Dairy for Protocol No.CLAF237A23135 in English.
94. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Hindi on 30-July-10.
95. The Insulin diary for protocol no. CLAF237A23135 in English.
96. The insulin diary for protocol No. CLAF237A23135 translated in Hindi on 31-July-10
97. Patient card for protocol No. CLAF237A23135 in English
98. Patient card for protocol No. CLAF237A23135 translated in Hindi on 29-July-10.
99. DCGI submission letter dated 06-Aug-10.
100. Certificate of Insurance for Protocol No.CLAF237A23135.

We also find one copy of principal investigator CV MRC and Investigator undertaking.

The members who attended the meeting held on 05.09.2010 at 03:30 PM, at which your proposal was discussed are listed below:

Sr. No.	Name	Qualification	Designation	Role in EC
1.	Mr. B.K. Tiwari	B.A. IDD	Retired DAD, Defence Services	Chairperson
2.	Dr. Ravi Gupta	MBBS, M.D. (Psy.)	Consultant Psychiatrist, S.R. Kalla Memorial Gastro & General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member Secretary
3.	Dr. Rakesh Yadav	MBBS, M.D. (Psy.)	Consultant Psychiatrist R.K. Yadav Memorial Mental Health & De addiction Hospital, Sirsi Road, Khatipura, Jaipur	Medical Scientist
4.	Dr. J. B. Gupta	MBBS, M.D.(Med.)	Consultant Physician & In charge ICU & Head Department of Clinical Research, S.R. Kalla Memorial Gastro and General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member
5.	Dr. Feroz Khan	MBBS, D.M.C.H.	General Physician, Jidan Clinic, Hasanpura, Jaipur & S.R. Kalla Memorial Gastro and General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member
6.	Dr. (Mrs.) Vandana Maheshwari	MBBS, M.S. (Gynae.)	Consultant Gynecologist, Jagatpura, Jaipur	Female Member
7.	Dr. Lalit Bharadia	MBBS, M.D. (Paediatrics), PDCC (Paediatric Gastroenterologist)	Consultant Paediatric gastroentrologist, Fortis Escort Hospital, Jaipur	Member
8.	Mr. Kawal Singh	B.Sc., LLB	Practicing Lawyer, Rajasthan High Court, Jaipur	Lawyer
9.	Mr. Mukesh Gupta	B.Sc., MBA (Marketing)	CEO, Zovaitalia Biotech Pharma Ltd., Jaipur	Social Scientist
10.	Mr. Ravi Kumar Sharma	M.Com., PGDCAA	Ministerial Staff, MNIT, Jaipur	Lay Person
11.	Mr. Vishnu Kumar Paliwal	B. Pharma	Marketing Executive, Lupin Limited, Jaipur	Pharmacist

The EC during its meeting decided to conditionally approve the trial to be conducted in its presented form. Following documents are pending from your site:

1. DCGI Approval letter
2. Clinical Trial Agreement

Kindly submit above mentioned and other study specific documents before initiation of any study activity.

There is no requirement of final approval for these documents for further conduct of above mentioned study. The documents are required only for notification.

It is hereby confirmed that neither you nor any of the study team members have participated in the voting/ decision making procedures of the committee and not even present at the time of voting/decision making procedures.

Please note that you are required to follow the requirement given below for this study:

- Do not implement any deviation from or change to the protocol approved by this ethics committee without the prior written approval of this ethics committee.
- Deviation / changes to the approved protocol may be implemented without prior approval of this ethics committee only when necessary to eliminate immediate hazards to the subjects or when changes involve only logistical or administrative aspects of the trial (e.g. change of study monitor(s), telephone number(s)).

Promptly report the following to the Ethics Committee:

- Any changes to or deviation to the protocol approved by this ethics committee that you may implement to eliminate hazards to the trial subjects.
- Any changes in the approved Informed Consent Form.
- All Serious Adverse Events (SAE).
- New information that may affect adversely the safety of the subjects or the conduct of the trial.

Please submit the following reports to the Ethics Committee:

- Annual report about the progress of the study.
- A copy of final study report.

The ethics committee is organized and operates according to the requirements of Good Clinical practice (GCP), Schedule Y and Indian Council of Medical Research (ICMR).

Yours sincerely,

Mr. B.K. Tiwari
Chairperson, Ethics Committee
Date: 07/09/2010
(DD/MM/YYYY)

Dr. Ravi Gupta
Member Secretary, Ethics Committee
Date: 07/09/2010
(DD/MM/YYYY)

S.R. Kella Memorial Ethical Committee for Human Research
28, Dadhichee G... Sardar Patel Marg, ... Phone No. +91-141-...

S.R. KALLA MEMORIAL ETHICAL COMMITTEE FOR HUMAN RESEARCH

78, Dhuleshwar Garden, Behind HSBC Bank, Sardar Patel Marg, C-Scheme, JAIPUR - 302 001
Phone: 0141-5112042, 5112043

Date .....

Date : 07 September, 2010 Ref.:94/10

Mr. B.K. Tiwari
Chairman
(B.A., DAD)

Dr. Ravi Gupta
Member Secretary
(MBBS, M.D. (Psy.))

Members:

Dr. Rakesh Yadav
MBBS, M.D. (Psy.)

Dr. J. B. Gupta
(MBBS, M.D.(Med.))

Dr. Feroz Khan
(MBBS, D.M.C.H.)

Dr. Lalit Bharadia
(MBBS, M.D. (Paediatrics), PDCC (Paediatric Gastroenterologist))

Dr. (Mrs.) Vandana Maheshwari
MBBS, M.S. (Gynae.)

Dr. (Mrs.) Madhvander Jain
MBBS, M.S. (Gynae.)

Mr. Kawal Singh
(B.Sc., LLB)

Mr. Mukesh Gupta
B.Sc., MBA (Marketing)
Director, Lions Club Jaipur Rajdhani

Mr. Ravi Kumar Sharma
(M.Com., PGDCAA)

Mr. Vishnu Kumar Paliwal
(B. Pharma)

To,

Dr. J.B. Gupta
S.R. Kalla Memorial Gastro & General Hospital,
No: 78, Dhuleshwar Garden, Behind HSBC Bank,
Sardar Patel Marg, C-Scheme,
Jaipur - 302001

Ref :- ***"A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin alone or with metformin, in patients with Type 2 diabetes mellitus".***

Study code: **Protocol CLAF237A23135**

Subject: Ethics Committee Approval for the Conduct of the Study as per Protocol **CLAF237A23135**

Dear Dr. Gupta

We have received 12 copies of following documents by your submission letter reference 1145/2010, dated 28.08.2010 for the approval:

1. The Study protocol CLAF237A23135 dated 8-July-10.
2. The Investigator Brochure Edition 14 dated 27-May-10.
3. Investigator Notification for vildagliptin/metformin: Dyspnoea (fatal) PHHY2010BR17904 dated 1-April-10
4. Investigator Notification for vildagliptin/metformin: Bronchial carcinoma (progression), blood amylase increased – PHHY2010DE05790 – dated 1 April-10
5. Investigator Notification for vildagliptin/metformin: Anal fistula – PHHY2010BR19223 dated 6-April-10.
6. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder– PHHY2010MX19011-dated 8-April-10
7. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 – dated 9-April-10

8. Investigator Notification for vildagliptin/metformin: Diabetic complication and renal disorder – PHHY2010BR19735 dated 12-April-10
9. Investigator Notification for vildagliptin/metformin: Uterine disorder– PHHY2010BE21389 – 13-April-10
10. Investigator Notification for vildagliptin/metformin: Diabetic complication (fatal), Pyelonephritis (fatal) and Anaemia (fatal) – PHHY2010MX05199 – dated 20-April-10
11. Investigator Notification for vildagliptin/metformin: Agitation – PHHY2010FR21869 dated 20-April-10
12. Investigator Notification for vildagliptin/metformin: Disorientation and Poisoning – PHHY2010AR22699 dated 20-April-10
13. Investigator Notification for vildagliptin/metformin: Nosocomial infection and Osteomyelitis dated 20-April-10
14. Investigator Notification for vildagliptin/metformin: Thyroid operation - PHHY2010BR22360 – dated 20-April-10
15. Investigator Notification for vildagliptin: Dermatitis bullous – PHHY2010FR22668 – dated 21-April-10
16. Investigator Notification for vildagliptin/metformin: Pulmonary embolism (fatal), venous insufficiency (fatal) and hypertension (fatal) – PHHY2010MX04398- dated 21-April-10
17. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823- dated 22-April-10
18. Investigator Notification for vildagliptin: Somnolence – PHHY2010ES21948 dated 22-April-10
19. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 dated 23-April-10
20. Investigator Notification for vildagliptin/metformin: Parkinsonism and Erysipelas – PHHY2010DE24400- 26-April-10
21. Investigator Notification for vildagliptin: Lymphoma (fatal) – PHHY2010AR26217 – dated 29-April-10

22. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder and nephrolithiasis – PHHY2010MX19011 dated 30-April-10
23. Investigator Notification for vildagliptin/metformin: Feeling abnormal – PHHY2010BR24339 – dated 30-April-10
24. Investigator Notification for vildagliptin/metformin: Hepatitis toxic and Barrett's oesophagus- dated 30-April-10
25. Investigator Notification for vildagliptin/metformin: Pancytopenia – PHHY2010FR26370 – dated 5- May-10
26. Investigator Notification for vildagliptin: Myeloid leukemia –PHHY2010KR26860 dated 7-May-10
27. Investigator Notification for vildagliptin/metformin:Hypertensive crisis– PHHY2010DE17676 – dated 12-May-10
28. Investigator Notification for vildagliptin/metformin: Angioplasty, Road traffic accident – PHHY2010MX28077 dated 12-May-10
29. Investigator Notification for vildagliptin/metformin: Urogenital disorder – PHFR2010GB00461 – dated 14-May-10
30. Investigator Notification for vildagliptin/metformin: Anaphylactic reaction – PHHY2010FR18881 dated 14-May-10
31. Investigator Notification for vildagliptin/metformin: Poisoning – PHHY2010MX28393 – dated 14-May-10
32. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis chronic – PHHY2010RU11562 dated 19-May-10
33. Investigator Notification for vildagliptin/metformin : Jaw operation – PHFR2010GB00532 – dated 19-May-10
34. Investigator Notification for vildagliptin: Infected skin ulcer (fatal) and osteomyelitis (fatal) – PHHY2010AR24350 dated 20-May-10
35. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis acute and Hydronephrosis – PHHY2010RU11165 dated 20-May-10.
36. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823 dated 20-May-10

37. Investigator Notification for vildagliptin/metformin: Feeling abnormal (life threatening) – PHHY2010BR31153 dated 21-May-10
38. Investigator Notification for vildagliptin/metformin: Hypertension (fatal) – PHHY2010AR31496 – dated 25-May-10
39. Investigator Notification for vildagliptin: Glaucoma – PHHY2010MX31604 – dated 25-May-10
40. Investigator Notification for vildagliptin/metformin: Hepatic failure – PHHY2010FR31991 dated 27-May-10
41. Investigator Notification for vildagliptin/metformin: Fall (fatal) – PHHY2010DE32526 - dated 28-May-10
42. Investigator Notification for vildagliptin/metformin: Neoplasm malignant (fatal) – PHHY2010MX32493 dated 28-May-10
43. Investigator Notification for vildagliptin/metformin: Diabetes insipidus (fatal), Brain oedema (fatal) and Respiratory arrest (fatal) – PHHY2010MX32892 dated 28-May-10
44. Investigator Notification for vildagliptin/metformin: Cytolytic hepatitis, Hepatotoxicity – PHHY2010FR32018 - dated 28-May-10
45. Investigator Notification for vildagliptin: Vision blurred – PHHY2010MX33002 – dated 31-May-10
46. Investigator Notification for vildagliptin/metformin: Muscle contractions involuntary and muscle rigidity – PHHY2010AR32862 dated 31-May-10
47. Investigator Notification for vildagliptin/metformin: Hepatitis toxic, Barrett's oesophagus and Haemochromatosis – PHHY2010DE25008 dated 31-May-10
48. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 31-May-10
49. Investigator Notification for vildagliptin/metformin: Cardiac valve disease – PHHY2010MX33389 dated 2-June-10
50. Investigator Notification for vildagliptin/metformin: Breast neoplasm – PHHY2009MX47365 – dated 7-June-10
51. Investigator Notification for vildagliptin/metformin: Hepatomegaly – PHHY2010FR 4686 - dated 7- June -10

52. Investigator Notification for vildagliptin: Osteoporosis – PHHY2010BR34361 –dated 7-June -10
53. Investigator Notification for vildagliptin/metformin: Knee arthroplasty PHHY2010MX34922 dated 8- June -10
54. Investigator Notification for vildagliptin: Glaucoma, Macular degeneration – PHHY2010MX31604 – dated 8- June -10
55. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic – PHHY2010MX34733 dated 8- June -10
56. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic and herpes zoster oticus – PHHY2010MX34733 - dated 9- June -10
57. Investigator Notification for vildagliptin/metformin: Hepatic failure, Pancreatic carcinoma metastatic – PHHY2010FR31991 - dated 9- June -10
58. Investigator Notification for vildagliptin: Blood pressure decreased – PHHY2010JP36133 – dated 10- June -10
59. Investigator Notification for vildagliptin/metformin: Diverticulitis– PHHY2010DE36823 dated 14- June -10
60. Investigator Notification for vildagliptin/metformin: Colitis – PHHY2010MX36727 - 15-June -10
61. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764 – dated 15- June -10
62. Investigator Notification for vildagliptin: Hypoaesthesia and large intestine perforation– PHHY2010MX36811- dated 16- June -10
63. Investigator Notification for vildagliptin/metformin: Diabetic nephropathy – PHHY2010DE23979 dated 16- June -10
64. Investigator Notification for vildagliptin/metformin: Chronic obstructive pulmonary disease – PHHY2010NO37552 dated 16- June -10
65. Investigator Notification for vildagliptin/metformin: Hepatomegaly and hepatic cirrhosis – PHHY2010FR34686 - dated 21- June -10
66. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 21- June -10

67. Investigator Notification for vildagliptin: Obesity surgery – PHHY2010BR37976 – dated 21-June -10
68. Investigator Notification for vildagliptin: Gastric ulcer perforation – PHHY2010MX38088 – dated 21- June -10
69. Investigator Notification for vildagliptin/metformin: Cardiogenic shock (fatal) and cytolytic hepatitis – PHHY2010FR38922 - dated 22- June -10
70. Investigator Notification for vildagliptin/metformin: Drug interaction – PHHY2010FR37623 - dated 24- June -10
71. Investigator Notification for vildagliptin/metformin: Irritable bowel syndrome – PHHY2010BR06953 – dated 29- June -10
72. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 30- June -10
73. Investigator Notification for vildagliptin: Delirium– PHHY2010JP40546 –dated 1-July-10
74. Investigator Notification for vildagliptin/metformin: Macular oedema – PHHY2010DE41585 – dated 1- July -10
75. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – 5-July -10
76. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 12- July -10
77. Investigator Notification for vildagliptin/metformin: Hepatitis – PHHY2010DE45018 – 16-July -10
78. Investigator Notification for vildagliptin: Hepatitis cholestatic– PHHY2010JP45330 – dated 16- July -10
79. Investigator Notification for vildagliptin: Jaundice – PHHY2010JP45195– dated 16- July -10
80. Investigator Notification for vildagliptin: Ileus – PHHY2010JP45206 – 20- July -10
81. Investigator Notification for vildagliptin/metformin: Abscess limb – PHHY2010MX44960 – 20- July -10
82. Investigator Notification for vildagliptin: Stent placement – PHHY2010AR45723-dated 22-July -10
83. Investigator Notification for vildagliptin/metformin: Traumatic lung injury – PHHY2010BR45810 – 22- July -10

84. Investigator Notification for vildagliptin/metformin: Fall (fatal), Head injury (fatal) – PHHY2010DE32526 - dated 22- July -10
85. Investigator Notification for vildagliptin/metformin: Typhoid fever– PHHY2010MX-6657 - 26- July -10
86. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764- 30- July -10
87. Investigator Notification for vildagliptin: Hepatic cirrhosis (fatal) – PHHY2010EC47345 – dated 29- July -10
88. Investigator Notification for vildagliptin/metformin: Mouth ulceration – PHHY2010GR47082 – dated 29- July -10
89. Investigator Notification for vildagliptin/metformin: Cholestasis – PHHY2010FR48667 – 3- August-10
90. The Electronic Case Report Form (eCRF) Layout dated 14-July-10.
91. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol in English.
92. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol translated in Hindi Language on 28-July-10.
93. The Glycemia Study Dairy for Protocol No.CLAF237A23135 in English.
94. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Hindi on 30-July-10.
95. The Insulin diary for protocol no. CLAF237A23135 in English.
96. The insulin diary for protocol No. CLAF237A23135 translated in Hindi on 31-July-10
97. Patient card for protocol No. CLAF237A23135 in English
98. Patient card for protocol No. CLAF237A23135 translated in Hindi on 29-July-10.
99. DCGI submission letter dated 06-Aug-10.
100. Certificate of Insurance for Protocol No.CLAF237A23135.

We also find one copy of principal investigator CV MRC and Investigator undertaking.

The members who attended the meeting held on 05.09.2010 at 03:30 PM, at which your proposal was discussed are listed below:

Sr. No.	Name	Qualification	Designation	Role in EC
1.	Mr. B.K. Tiwari	B.A. IDD	Retired DAD, Defence Services	Chairperson
2.	Dr. Ravi Gupta	MBBS, M.D. (Psy.)	Consultant Psychiatrist, S.R. Kalla Memorial Gastro & General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member Secretary
3.	Dr. Rakesh Yadav	MBBS, M.D. (Psy.)	Consultant Psychiatrist R.K. Yadav Memorial Mental Health & De addiction Hospital, Sirsi Road, Khatipura, Jaipur	Medical Scientist
4.	Dr. J. B. Gupta	MBBS, M.D.(Med.)	Consultant Physician & In charge ICU & Head Department of Clinical Research, S.R. Kalla Memorial Gastro and General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member
5.	Dr. Feroz Khan	MBBS, D.M.C.H.	General Physician, Jidan Clinic, Hasanpura, Jaipur & S.R. Kalla Memorial Gastro and General Hospital, Sardar Patel Marg, C-Scheme, Jaipur	Member
6.	Dr. (Mrs.) Vandana Maheshwari	MBBS, M.S. (Gynae.)	Consultant Gynecologist, Jagatpura, Jaipur	Female Member
7.	Dr. Lalit Bharadia	MBBS, M.D. (Paediatrics), PDCC (Paediatric Gastroenterologist)	Consultant Paediatric gastroentrologist, Fortis Escort Hospital, Jaipur	Member
8.	Mr. Kawal Singh	B.Sc., LLB	Practicing Lawyer, Rajasthan High Court, Jaipur	Lawyer
9.	Mr. Mukesh Gupta	B.Sc., MBA (Marketing)	CEO, Zovaitalia Biotech Pharma Ltd., Jaipur	Social Scientist
10.	Mr. Ravi Kumar Sharma	M.Com., PGDCAA	Ministerial Staff, MNIT, Jaipur	Lay Person
11.	Mr. Vishnu Kumar Paliwal	B. Pharma	Marketing Executive, Lupin Limited, Jaipur	Pharmacist

The EC during its meeting decided to conditionally approve the trial to be conducted in its presented form. Following documents are pending from your site:

1. DCGI Approval letter
2. Clinical Trial Agreement

Kindly submit above mentioned and other study specific documents before initiation of any study activity.

There is no requirement of final approval for these documents for further conduct of above mentioned study. The documents are required only for notification.

It is hereby confirmed that neither you nor any of the study team members have participated in the voting/ decision making procedures of the committee and not even present at the time of voting/decision making procedures.

Please note that you are required to follow the requirement given below for this study:

- Do not implement any deviation from or change to the protocol approved by this ethics committee without the prior written approval of this ethics committee.
- Deviation / changes to the approved protocol may be implemented without prior approval of this ethics committee only when necessary to eliminate immediate hazards to the subjects or when changes involve only logistical or administrative aspects of the trial (e.g. change of study monitor(s), telephone number(s)).

Promptly report the following to the Ethics Committee:

- Any changes to or deviation to the protocol approved by this ethics committee that you may implement to eliminate hazards to the trial subjects.
- Any changes in the approved Informed Consent Form.
- All Serious Adverse Events (SAE).
- New information that may affect adversely the safety of the subjects or the conduct of the trial.

Please submit the following reports to the Ethics Committee:

- Annual report about the progress of the study.
- A copy of final study report.

The ethics committee is organized and operates according to the requirements of Good Clinical practice (GCP), Schedule Y and Indian Council of Medical Research (ICMR).

Yours sincerely,

Mr. B.K. Tiwari
Chairperson, Ethics Committee
Date: 07/09/2010
(DD/MM/YYYY)

Dr. Ravi Gupta
Member Secretary, Ethics Committee
Date: 07/09/2010
(DD/MM/YYYY)

S.R. Kella Memorial Ethical Committee for Human Research
28, Dadhichee G... Sardar Patel Marg, ... Phone No. +91-141-...

Ethics Committee for Research on Human Subjects
(Established 1986)
Seth G. S. Medical College & K.E.M. Hospital, Parel, Mumbai - 400 012.
Office : Dept. of Pharmacology & Therapeutics, 1st Floor, College Building.
Tel. No.: 91-22-2413 6051 (Ext. : 2515), Cell : 9820757259 e-mail : ethicscommittee@kem.edu

EC / OUT / 33 / 11

Date: 7th January 2011

To,

Dr. Nalini Shah,

Dept. of Endocrinology

Ref: Your project no. **EC/PHARMA-25/2010** entitled, Clinical Trial Protocol Study CLAF237A23135 Release date: 8-July-10, "A 24 week, multi centre, double blind, randomized, placebo- controlled, parallel-group Study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to Insulin, with or without metformin, in patients with type 2 diabetes mellitus".

Sub: Letter no. KEM/ENDO/Novartis/01/11 dated 5th January 2010 regarding submission of final Clinical Trial Agreement and DCGI permission letter.

Dear Dr. Shah,

The meeting of the Ethics Committee for Research on Human Subjects (ECRHS) was held on 16th December 2010 at 1.30 p.m., in the Clinical Pharmacology Seminar Hall with Dr. Manu Kothari as the Chairperson.

Eleven members attended the meeting held on 16th December 2010. The list of members who attended the meeting is as follows.

Name of Members	Position on Ethics Committee	Designation & Affiliation	Qualification
1. Dr. Manu Kothari	Chairperson (External)	-	M.S., M. SC. (Anatomy)
2. Dr. Padmaja Marathe	Member Secretary	Associate Professor (Pharmacology& Therapeutics) GSMC & KEMH	M.D.
3. Dr. Sandeep Bavdekar	Member (External Scientific Expert)	Professor and Head (Pediatrics) TN Medical College and BYL Nair Hospital.	M.D., D.C.H.
4. Dr. Kaizad Damania	Member (External Scientific Expert)	Professor (Obstetrics & Gynaecology) N. Wadia Maternity Hospital	M. D., DNB., F.C.P.S., D.G.O., D.F.P.
5. Mrs. Manisha Naik Dalal	Member (External Layperson)	-	M.Com
6. Dr. (Mrs.) Helen Joseph	Member (External Social Worker)	Faculty Member College of Social Work of Nirmala Niketan Institute	M.S.W., M. Phil., Ph.D.

7. Dr. Sandhya Kamat	Member	Professor (Pharmacology& Therapeutics) GSMC & KEMH	M.D.
8. Dr. Sunil Kuyare	Member	Assistant Professor, (Microbiology) GSMC & KEMH	M.D., DHA, FME.
9. Dr. Milind Y. Nadkar	Member	Professor, (Medicine) GSMC & KEMH	M.D., FICP
10. Dr. Urmila Thatte	Member	Professor & Head (Clinical Pharmacology) GSMC & KEMH	M.D., DNB., Ph.D.
11. Dr. D. N. Upasani	Member (External Legal Expert)	Medical Director, Ghatkopar Hindusabha Hospital Mumbai	M.S., L.L.B.

It is to be noted that neither you nor any of your proposed study team members were present during the decision-making procedures of the Ethics Committee for Research on Human Subjects.

The ECRHS reviewed the above – mentioned clinical study and approved the following documents submitted for this clinical study at the meeting.

1. The Study protocol CLAF237A23135 dated 8-July-10.
2. The Electronic Case Report Form (eCRF) Layout dated 14-July-10.
3. The Glycemia Study Dairy for Protocol No.CLAF237A23135 in English.
4. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Hindi on 30-July-10.
5. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Gujarati on 30-July-10.
6. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Marathi on 30-July-10.
7. The Insulin diary for protocol no. CLAF237A23135 in English.
8. The insulin diary for protocol No. CLAF237A23135 translated in Hindi on 31- July-10
9. The insulin diary for protocol No. CLAF237A23135 translated in Gujarati on 31- July-10
10. The insulin diary for protocol No. CLAF237A23135 translated in Marathi on 31- July-10
11. Patient card 18-Jun-2010 for protocol No. CLAF237A23135 in English
12. Patient card 18-Jun-2010 for protocol No. CLAF237A23135 translated in Hindi on 29-July-10.
13. Patient card 18-Jun-2010 for protocol No. CLAF237A23135 translated in Gujarati on 30-July-10.
14. Patient card 18-Jun-2010 for protocol No. CLAF237A23135 translated in Marathi on 29-July-10.
15. Certificate of Insurance for Protocol No.CLAF237A23135.
16. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 in English.

17. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 translated from English to Marathi on 18 November 2010
18. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 translated from English to Hindi on 17 November 2010
19. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 translated from English to Gujarati on 17 November 2010
20. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 back translated from Marathi to English on 18 November 2010
21. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 back translated from Hindi to English on 17 November 2010
22. Informed Consent Form India: Core Study Version 1.2: dated 12/Nov/2010 back translated from Gujarati to English on 17 November 2010
23. Investigator Brochure Edition 14, dated 27 May 2010
24. A copy of log of delegation of responsibilities of the study team members.
25. A copy of investigator undertaking signed on 28th June 2010.
26. Ethics Committee permission of Independent Human Ethics Committee Trivandrum, Veridian Ethics Committee Nashik, Credo Independent Ethics Committee Mumbai.
27. Temporary CTRI registration number: REFCTRI- 2010001276
28. A copy of your curriculum vitae signed on 7th June 2010
29. A copy of your GCP training certificate
30. Curriculum vitae of Dr. Tushar Bandgar signed on 20th August 2010, Dr. V. Shivane signed on 20th August 2010, Dr. Nilam Adivarekar signed on 19th August 2010 and Mr. Harshad Dere.
31. A copy of GCP training certificate of Dr. Tushar Bandgar, Dr. V. Shivane and Dr. Nilam Adivarekar.

Subsequently the following documents were received by the ECRHS on 5th January 2011 were reviewed and approved.

1. Final Clinical Trial Agreement.
2. DCGI permission letter dated 14th December 2010.

The ECRHS hereby approves the proposal entitled, **Clinical Trial Protocol Study CLAF237A23135 Release date: 8-July-10, "A 24 week, multi centre, double blind, randomized, placebo-controlled, parallel-group Study to assess the efficacy and safety of vildagliptin 50mg bid as**

an add-on therapy to Insulin, with or without metformin, in patients with type 2 diabetes mellitus".

The SAE reports also have been reviewed and noted by the ECRHS in its records.

It is understood that the study will be conducted under your direction, in a total of 30 subjects, at Department of Endocrinology, Seth G. S. Medical College and K.E.M. Hospital as per the submitted protocol.

This approval is valid for the entire duration of the study.

It is the policy of ECRHS that it be informed about any serious adverse event occurring during the course of the study within seven working days of the occurrence of the adverse event. If 'Death' is a SAE, it should be reported to the ECRHS within 24 hours of its occurrence via an email.

No deviations from, or changes of the protocol and Informed Consent Document should be initiated without prior written approval by the ECRHS of an appropriate amendment. The ECRHS expects that the investigator should promptly report to the ECRHS any deviations from, or changes of, the protocol to eliminate immediate hazards to the trial subjects and about any new information that may affect adversely the safety of the subjects or the conduct of the trial.

For studies which will continue for more than a year, a continuing review report needs to be submitted (within 1 month of the due date i.e. 13 months from the date of approval) on or before 7th February 2012.

A copy of the final report should be submitted to the ECRHS for review.

Sincerely yours,

Dr. M. L. Kothari
Chairperson

Date of approval of the study: 07/01/2011

CENTRAL INDIA MEDICAL RESEARCH ETHICS COMMITTEE, NAGPUR

DR. S. M. PATIL
Chairperson
Cell : 93731 01673

DR. ANJALI BHANDARKAR
Member Secretary
Cell : 98232 75423

MEMBERS

DR. (MRS.) M. P. HOLAY
Cell : 97665 41270

DR. RAJAN BAROKAR
Cell : 98230 83037

DR. ANAND SAOJI
Cell : 98231 23457

DR. S. D. KHANZODE
Cell : 98503 99440

ADV. ATUL P. SHENDE
Cell : 9822571644

Rev. JOY RAO
Cell : 9665037345

MR. D. K. BHOYAR
Cell : 9823186315

Date: 31 Mar.2011

To,

Dr. Pramod Gandhi,
Gandhis Research Institute,
Shreewardhan Complex, Wardha Road, Ramdaspeth
Nagpur (MS)-440010, India.

Protocol no:- CLAF237A23135

Study Title: : "A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin alone or with metformin, in patients with Type 2 diabetes mellitus"

Subject: Approval of ICF Version 2 dated 25 Jan 2011 for the mention study

Dear Dr. Pramod Gandhi,

This is with reference to your submission letter dated 21 Mar 2011 for the approval of the referenced study documents. In the Ethics Committee meeting held on 28 Mar 2011 your application about study documents for the above referenced clinical trial was discussed and the following documents were reviewed and approved.

Sr No	Content
1	The Patient Information and Informed Consent Form Version 2 dated 25 Jan 2011
2	The Patient Information and Informed Consent Form Version 2 dated 25 Jan 2011.Translated in Hindi on 1 Mar 2011
3	The Patient Information and Informed Consent Form Version 2 dated 25 Jan 2011.Translated in Marathi on 1 Mar 2011

The convened meeting held on 28 Mar 2011at 5.30 p.m. at Dr.Patil Hospital, Yugdharma Complex, Ramdaspeth, Nagpur was attended by:

Sr. No.	Name of the member	Role in the EC.	Qualification
1	Dr. S.M. Patil	Chairperson	M.D Medicine
2	Dr.Mrs. Anjali Bhandarkar	Member Secretary	M.D Gynecology ,B.A (Psychology)
3	Dr. Mrs.M.P.Holay	Clinician Member	M.D Medicine
4	Dr.Rajan Borkar	Intensivist Clinician	M.D Medicine

5	Adv.Atul P. Shende	Legal Expert Member	LL.B
6	Mrs. Joy Rao	Theologist	M.A Theologist, Ministry of World Missionary Evangelism
7.	Mr.D.K.Bhoyar	Lay person	B.A

The Central India Medical research Ethics Committee, Nagpur should be informed about the following-

1. Progress of the study
2. Any SAE occurring in the course of the study
3. Any changes in the protocol and patient information/informed consent
4. A copy of the final report.

We hereby confirm that neither Principal Investigator nor his team members participated in the voting procedures for the referenced study.

We approve the trial to be conducted in its presented form. The Ethics committee of this institution is duly constituted, has written procedures for initial and continuing review of clinical trials, prepares written minutes of convened meetings, and retains records pertaining to review and approval process; all in compliance with requirements defined in the International Conference of Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and Indian regulatory guidelines. Access of Ethics of Committee records and communications would be granted to authorize individuals during audits / inspections conducted by regulatory authorities.

Yours Sincerely,

CENTRAL INDIA MEDICAL RESEARCH ETHICS COMMITTEE Nagpur, India

Dr S. M. Patil
The Chairperson-Central India Medical Research Ethics Committee,
Yugadharma Complex, Ramdaspeth, Nagpur (MS) India – 440010.

CHAIRPERSON
CENTRAL INDIA MEDICAL RESEARCH ETHICS COMMITTEE, NAGPUR

Veridian Ethics Committee

Off. 5, Yogchaitanya, Kalpana Nagar, Off. College Road, Nashik - 422 005.
Tel. : + 91 253 2575624, +91 9420484010, E-mail : veridianec@gmail.com

Date: 08th Sep 2011
To,
Dr. Sujit Chandratreya
Endocare Clinic, Mohiniraj,
Gangapur road,
Nashik-422013

Ref: Protocol No: CLAF237A23135 "A 24-week, multi center, double blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin alone or with metformin in patients with type 2 diabetes mellitus"

Subject: Ethics Committee approval

Dear Dr.Sujit Chandratreya,

This is with reference to your letter dated 23rd Aug 2011 for study approval for the above mentioned study. The study was reviewed by **Veridian Ethics Committee at 5 Yogchaitanya, Kalpana Nagar, Off College Road, Nasik 422005,** in its meeting dated 1st Sep 2011 at 9:30 a.m. We further approve the above mentioned study for a period of 1 year.

The ethics committee has conducted a scientific and ethical review of the study and hereby grants you permission to conduct the clinical study. This approval is valid until 1 year as per the EC norms.

The following members attended the ethics committee meeting for the review of this clinical study. This satisfies the quorum necessary for such meetings of this ethics committee.

Sr. No.	Name and Gender	SEX	Qualification	Affiliation/ Designation within EC	Primary Scientific or non Scientific speciality
1	Dr. Priyavat Jaitli	M	MD(PATH)	Chairperson	Basic Scientist
2	Mr.Gandhar Vishwas Mandlik	M	B.E.	Member Secretary	Social Worker
3	Mr. Ajit Kantilal Challani	M	L.LB	Member	Advocate

Veridian Ethics Committee

Off. 5, Yogchaitanya, Kalpana Nagar, Off. College Road, Nashik - 422 005.
Tel. : + 91 253 2575624, +91 9420484010, E-mail : veridianec@gmail.com

4	Dr.Geetanjali Pawar	F	BHMS	Member	Clinician-Alternate Medicine
5	Dr. Naina Priyavart Jaitli	F	MD(Gynaec.)	Member	Clinician
6	Mr. Kavrilal Makhamal Sakhala	M	B.Pharm	Member	Pharmacist
7	Ms. Namrata Rodge	F	B.C.S.	Member	Lay Person

The same was approved with 7 votes in favour of the study as against 0 votes against the study. We confirm that you did not participate in the deliberations of the ethics committee for this study and did not vote on the proposal for this study.

The full composition of this ethics committee is as below:

Sr. No.	Name and Gender	SEX	Qualification	Affiliation/ Designation within EC	Primary Scientific or non Scientific speciality
1	Dr. Priyavat Jaitli	M	MD(PATH)	Chairperson	Basic Scientist
2	Mr.Gandhar Vishwas Mandlik	M	B.E.	Member Secretary	Social Worker
3	Mr. Ajit Kantilal Challani	M	L.LB	Member	Advocate
4	Dr. Geetanjali Pawar	F	BHMS	Member	Clinician-Alternate Medicine
5	Dr. Naina Priyavart Jaitli	F	MD(Gynaec.)	Member	Clinician
6	Mr. Kavrilal Makhamal Sakhala	M	B.Pharm	Member	Pharmacist
7	Ms. Namrata Rodge	F	B.C.S.	Member	Lay Person

Veridian Ethics Committee

Off. : 5, Yogchaitanya, Kalpana Nagar, Off. College Road, Nashik - 422 005.
Tel. : + 91 253 2575624, +91 9420484010, *E-mail* : veridianec@gmail.com

Please note that you are required to follow the requirements given below for this study:

Do not implement any deviation from, or change to, the protocol approved by this ethics committee without the prior written approval of this ethics committee. Deviations/ changes to the approved protocol may be implemented without prior approval of this ethics committee only when necessary to eliminate immediate hazards to subjects or when changes involve only logistical or administrative aspects of the trial [e.g. change of study monitor(s), telephone numbers(s)].

Promptly report to this ethics committee:

- Any changes to or deviations to the protocol approved by this ethics committee that you may implement to eliminate hazards to the trial subjects.
- All serious adverse events.
- New information that may affect adversely the safety of the subjects or the conduct of the trial.

This ethics committee is organized and operates according to the requirements of ICH –GCP, requirements of the Indian Council of Medical Research (ICMR), local laws and regulatory requirements of India.

Yours sincerely,

8-9-15

Chairperson/Member Secretary, Ethics Committee.

(Sign, date and stamp) Mr. Sridhar Mandik

Member Secretary
Veridian Ethics Committee
5, Yogchaitanya, Kalpana Nagar,
Opp. College Road, Nashik - 422 005.
E-mail: veridianec@gmail.com

BHARTI RESEARCH INSTITUTE OF DIABETES & ENDOCRINOLOGY
(B.R.I.D.E.)
INSTITUTIONAL ETHICS COMMITTEE
Ph. : 0184-2268585
Fax : 0184-2267885
WAZIR CHAND COLONY, KUNJPURA ROAD, KARNAL-132 001

Date..... **Date: 26-Sep-2010**

Ref. No..... Ref.BRIDE-IEC-09-26

To,

Dr. Sanjay Kalra
Bharti Research Institute of Diabetes and Endocrinology (B.R.I.D.E)
Wazir Chand Colony
Kunjpura Road
Karnal – 132 001
Haryana

Subject: Ethics Committee Approval for the Conduct of the Study as per Protocol **CLAF237A23135**, titled ***"A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin alone or with metformin, in patients with Type 2 diabetes mellitus".***

Study code: Protocol CLAF237A23135

Dear Dr. Sanjay Kalra,

The Ethics committee meeting was held on date **25-Sep-2010.** The following members attended the Ethics Committee meeting for the review of this clinical study. This satisfies the quorum necessary for such meetings of this Ethics Committee:-

Name, Gender **and Role**	**Title**	**Affiliation** (Name of Institute/ Organisation, or None)
Dr.Vinod Goyal, Female, Member	*MD(Pathology)*	*Consultant City Lab, Karnal*
Dr.Vinod Sharma, Male, Member	*D.A,Anaesthetist*	*Consultant Anaesthist, Karnal*
Fr.Amrit Raj, Male, Member	**BTheo, MBA**	*Head Pragati Society, Karnal*
Mrs.Sneh Sawhney, Female,Chairperson	*M.A,M.Ed*	*Principal,Mother Care School,Karnal*
Dr.Bharti Kalra, Female, Member Secretary	*MD(Gynaecology)*	*B.R.I.D.E*

Dr.Sarita Chatley, Female, Member	*DCH (Paediatrician)*	*Consultant, Uttam Clinic, Karnal*
Dr.Anuj Thakur, Male, Member	*MBBS,DNB (Paediatrician)*	*Consultant, Thakur Nursing Home, Karnal*
Mr.Shravan Kumar, Male, Member	*BA(Hons), LLB*	*Lawyer Dist court,Kurukshetra*
Dr.Sanjay Kalra, Male, Member	*DM(Endocrinology)*	*B.R.I.D.E*

The Ethics committee has reviewed and approved the following documents received from you via your letter dated ***20-Sep-2010:-***

1. The Study protocol CLAF237A23135 dated 8-July-10.
2. The Investigator Brochure Edition 14 dated 27-May-10.
3. Investigator Notification for vildagliptin/metformin: Dyspnoea (fatal) PHHY2010BR17904 dated 1-April-10
4. Investigator Notification for vildagliptin/metformin: Bronchial carcinoma (progression), blood amylase increased – PHHY2010DE05790 – dated 1-April-10
5. Investigator Notification for vildagliptin/metformin: Anal fistula – PHHY2010BR19223 dated 6-April-10.
6. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder– PHHY2010MX19011-dated 8-April-10
7. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 – dated 9-April-10
8. Investigator Notification for vildagliptin/metformin: Diabetic complication and renal disorder – PHHY2010BR19735 dated 12-April-10
9. Investigator Notification for vildagliptin/metformin: Uterine disorder– PHHY2010BR21389 – 13-April-10
10. Investigator Notification for vildagliptin/metformin: Diabetic complication (fatal), Pyelonephritis (fatal) and Anaemia (fatal) – PHHY2010MX05199 – dated 20-April-10
11. Investigator Notification for vildagliptin/metformin: Agitation – PHHY2010FR21869 dated 20-April-10
12. Investigator Notification for vildagliptin/metformin: Disorientation and Poisoning – PHHY2010AR22699 dated 20-April-10
13. Investigator Notification for vildagliptin/metformin: Nosocomial infection and Osteomyelitis dated 20-April-10
14. Investigator Notification for vildagliptin/metformin: Thyroid operation - PHHY2010BR22360 – dated 20-April-10
15. Investigator Notification for vildagliptin: Dermatitis bullous – PHHY2010FR22668 – dated 21-April-10
16. Investigator Notification for vildagliptin/metformin: Pulmonary embolism (fatal), venous insufficiency (fatal) and hypertension (fatal) – PHHY2010MX04398- dated 21-April-10
17. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823- dated 22-April-10

18. Investigator Notification for vildagliptin: Somnolence – PHHY2010ES21948 dated 22-April-10
19. Investigator Notification for vildagliptin/metformin: Balance disorder – PHHY2010FR20307 dated 23-April-10
20. Investigator Notification for vildagliptin/metformin: Parkinsonism and Erysipelas – PHHY2010DE24400- 26-April-10
21. Investigator Notification for vildagliptin: Lymphoma (fatal) – PHHY2010AR26217 – dated 29-April-10
22. Investigator Notification for vildagliptin/metformin: Renal cancer, uterine disorder and nephrolithiasis – PHHY2010MX19011 dated 30-April-10
23. Investigator Notification for vildagliptin/metformin: Feeling abnormal – PHHY2010BR24339 – dated 30-April-10
24. Investigator Notification for vildagliptin/metformin: Hepatitis toxic and Barrett's oesophagus- dated 30-April-10
25. Investigator Notification for vildagliptin/metformin: Pancytopenia – PHHY2010FR26370 – dated 5- May-10
26. Investigator Notification for vildagliptin: Myeloid leukemia – PHHY2010KR26860 dated 7-May-10
27. Investigator Notification for vildagliptin/metformin:Hypertensive crisis– PHHY2010DE17676 – dated 12-May-10
28. Investigator Notification for vildagliptin/metformin: Angioplasty, Road traffic accident – PHHY2010MX28077 dated 12-May-10
29. Investigator Notification for vildagliptin/metformin: Urogenital disorder – PHFR2010GB00461 – dated 14-May-10
30. Investigator Notification for vildagliptin/metformin: Anaphylactic reaction – PHHY2010FR18881 dated 14-May-10
31. Investigator Notification for vildagliptin/metformin: Poisoning – PHHY2010MX28393 – dated 14-May-10
32. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis chronic – PHHY2010RU11562 dated 19-May-10
33. Investigator Notification for vildagliptin/metformin : Jaw operation – PHFR2010GB00532 – dated 19-May-10
34. Investigator Notification for vildagliptin: Infected skin ulcer (fatal) and osteomyelitis (fatal) – PHHY2010AR24350 dated 20-May-10
35. Investigator Notification for vildagliptin: Calculus urinary, Pyelonephritis acute and Hydronephrosis – PHHY2010RU11165 dated 20-May-10
36. Investigator Notification for vildagliptin: Abdominal neoplasm – PHHO2010BR03823 dated 20-May-10
37. Investigator Notification for vildagliptin/metformin: Feeling abnormal (life threatening) – PHHY2010BR31153 dated 21-May-10
38. Investigator Notification for vildagliptin/metformin: Hypertension (fatal) – PHHY2010AR31496 – dated 25-May-10
39. Investigator Notification for vildagliptin: Glaucoma – PHHY2010MX31604 – dated 25-May-10
40. Investigator Notification for vildagliptin/metformin: Hepatic failure – PHHY2010FR31991 dated 27-May-10
41. Investigator Notification for vildagliptin/metformin: Fall (fatal) – PHHY2010DE32526 - dated 28-May-10
42. Investigator Notification for vildagliptin/metformin: Neoplasm malignant (fatal) – PHHY2010MX32493 dated 28-May-10
43. : Investigator Notification for vildagliptin/metformin: Diabetes insipidus (fatal), Brain oedema (fatal) and Respiratory arrest (fatal) – PHHY2010MX32892 dated 28-May-10

44. Investigator Notification for vildagliptin/metformin: Cytolytic hepatitis, Hepatotoxicity – PHHY2010FR32018 - dated 28-May-10
45. Investigator Notification for vildagliptin: Vision blurred – PHHY2010MX33002 – dated 31-May-10
46. Investigator Notification for vildagliptin/metformin: Muscle contractions involuntary and muscle rigidity – PHHY2010AR32862 dated 31-May-10
47. Investigator Notification for vildagliptin/metformin: Hepatitis toxic, Barrett's oesophagus and Haemochromatosis – PHHY2010DE25008 dated 31-May-10
48. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 31-May-10
49. Investigator Notification for vildagliptin/metformin: Cardiac valve disease – PHHY2010MX33389 dated 2-June-10
50. Investigator Notification for vildagliptin/metformin: Breast neoplasm – PHHY2009MX47365 – dated 7-June-10
51. Investigator Notification for vildagliptin/metformin: Hepatomegaly – PHHY2010FR34686 - dated 7- June -10
52. Investigator Notification for vildagliptin: Osteoporosis – PHHY2010BR34361 – dated 7- June -10
53. Investigator Notification for vildagliptin/metformin: Knee arthroplasty PHHY2010MX34922 dated 8- June -10
54. Investigator Notification for vildagliptin: Glaucoma, Macular degeneration – PHHY2010MX31604 – dated 8- June -10
55. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic – PHHY2010MX34733 dated 8- June -10
56. Investigator Notification for vildagliptin/metformin: Herpes zoster ophthalmic and herpes zoster oticus – PHHY2010MX34733 - dated 9- June -10
57. Investigator Notification for vildagliptin/metformin: Hepatic failure, Pancreatic carcinoma metastatic – PHHY2010FR31991 - dated 9- June -10
58. Investigator Notification for vildagliptin: Blood pressure decreased – PHHY2010JP36133 – dated 10- June -10
59. Investigator Notification for vildagliptin/metformin: Diverticulitis– PHHY2010DE36823 dated 14- June -10
60. Investigator Notification for vildagliptin/metformin: Colitis – PHHY2010MX36727 - 15- June - 10
61. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764 – dated 15- June -10
62. Investigator Notification for vildagliptin: Hypoaesthesia and large intestine perforation– PHHY2010MX36811- dated 16- June -10
63. Investigator Notification for vildagliptin/metformin: Diabetic nephropathy – PHHY2010DE23979 dated 16- June -10
64. Investigator Notification for vildagliptin/metformin: Chronic obstructive pulmonary disease – PHHY2010NO37552 dated 16- June -10
65. Investigator Notification for vildagliptin/metformin: Hepatomegaly and hepatic cirrhosis – PHHY2010FR34686 - dated 21- June -10
66. Investigator Notification for vildagliptin: Liver function test abnormal – PHHY2010DE33138 - dated 21- June -10
67. Investigator Notification for vildagliptin: Obesity surgery – PHHY2010BR37976 – dated 21- June -10
68. Investigator Notification for vildagliptin: Gastric ulcer perforation – PHHY2010MX38088 – dated 21- June -10

69. Investigator Notification for vildagliptin/metformin: Cardiogenic shock (fatal) and cytolytic hepatitis – PHHY2010FR38922 - dated 22- June -10
70. Investigator Notification for vildagliptin/metformin: Drug interaction – PHHY2010FR37623 - dated 24- June -10
71. Investigator Notification for vildagliptin/metformin: Irritable bowel syndrome – PHHY2010BR06953 – dated 29- June -10
72. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 30- June -10
73. Investigator Notification for vildagliptin: Delirium– PHHY2010JP40546 –dated 1-July-10
74. Investigator Notification for vildagliptin/metformin: Macular oedema – PHHY2010DE41585 – dated 1- July -10
75. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – 5- July - 10
76. Investigator Notification for vildagliptin: Hypoglycaemic coma– PHHY2010JP40712 – dated 12- July -10
77. Investigator Notification for vildagliptin/metformin: Hepatitis – PHHY2010DE45018 – 16- July - 10
78. Investigator Notification for vildagliptin: Hepatitis cholestatic– PHHY2010JP45330 – dated 16- July -10
79. Investigator Notification for vildagliptin: Jaundice – PHHY2010JP45195– dated 16- July -10
80. Investigator Notification for vildagliptin: Ileus – PHHY2010JP45206 – 20- July -10
81. Investigator Notification for vildagliptin/metformin: Abscess limb – PHHY2010MX44960 – 20- July -10
82. Investigator Notification for vildagliptin: Stent placement – PHHY2010AR45723-dated 22- July - 10
83. Investigator Notification for vildagliptin/metformin: Traumatic lung injury – PHHY2010BR45810 – 22- July -10
84. Investigator Notification for vildagliptin/metformin: Fall (fatal), Head injury (fatal) – PHHY2010DE32526 - dated 22- July -10
85. Investigator Notification for vildagliptin/metformin: Typhoid fever– PHHY2010MX46657 -26- July -10
86. Investigator Notification for vildagliptin: Balance disorder and dysphagia – PHHY2010AU36764- 30- July -10
87. Investigator Notification for vildagliptin: Hepatic cirrhosis (fatal) – PHHY2010EC47345 – dated 29- July -10
88. Investigator Notification for vildagliptin/metformin: Mouth ulceration – PHHY2010GR47082 – dated 29- July -10
89. Investigator Notification for vildagliptin/metformin: Cholestasis – PHHY2010FR48667 – 3- August-10
90. The Electronic Case Report Form (eCRF) Layout dated 14-July-10.
91. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol in English.
92. The Patient Information and Informed Consent Form, Version1, dated 19-July-2010 for Study Protocol translated in Hindi Language on 28-July-10.
93. The Glycemia Study Dairy for Protocol No.CLAF237A23135 in English.
94. The Glycemia Study Dairy for Protocol No. CLAF237A23135 translated in Hindi on 30-July-10.
95. The Insulin diary for protocol no. CLAF237A23135 in English.
96. The insulin diary for protocol No. CLAF237A23135 translated in Hindi on 31-July-10
97. Patient card for protocol No. CLAF237A23135 in English

98. Patient card for protocol No. CLAF237A23135 translated in Hindi on 29-July-10.
99. DCGI submission letter dated 06-Aug-10.

100. Certificate of Insurance for Protocol No.CLAF237A23135

None of the Investigators and the members of the study team involved in the study participated in deliberations and voting of the said study during the meetings.

The Ethics committee functions as per the requirements of the ICH-GCP and their SOP's.

Please keep the Ethics Committee informed about any deviation / changes made to the protocol and all Adverse Events that are both serious and unexpected or any new information that may affect adversely the safety of the subjects participating in trial. You are also obliged to inform the progress of the study annually to the Ethics committee.

Chairperson

Dr. Sawhney
Diabetes Endocrinology
KARNAL
Sept 2010

Institutional Ethics Committee
INDIA